- Lloyd Price
Non-invasive blood glucose monitoring: emerging HealthTech sub sector is 'one to watch in 2024'
Exec Summary:
The non-invasive continuous blood glucose monitoring (NGBGM) market is expected to grow significantly in the coming years. This growth is being driven by a number of factors, including the increasing prevalence of diabetes, the rising demand for wearable devices, and the development of new NGBGM technologies that make blood glucose monitoring more convenient and affordable.
The growth of the NGBGM market is expected to drive M&A activity in the healthtech sub sector in 2024. Companies that are developing new NGBGM technologies or that are looking to expand their reach in the market are expected to be active in M&A deals.
Here are some of the key M&A trends predicted in the NGBGM market in 2024:
Acquisitions of startups: Startups are developing innovative NGBGM technologies that could be acquired by larger companies. These acquisitions would allow the larger companies to acquire the technology and expertise of the startups, and to accelerate the development and commercialization of NGBGM products.
Partnerships between device manufacturers and healthcare providers: Device manufacturers and healthcare providers could partner to develop and market NGBGM solutions. These partnerships would allow the device manufacturers to gain access to healthcare providers' networks and expertise, and to help to ensure that NGBGM products are used effectively.
Joint ventures between companies in different parts of the value chain: Companies in different parts of the NGBGM value chain, such as device manufacturers, software developers, and healthcare providers, could form joint ventures to develop and market new solutions. These joint ventures would allow companies to share resources and expertise, and to reduce the risks associated with developing and commercializing NGBGM products.
The NGBGM market is still in its early stages of development, but it is expected to grow rapidly in the coming years. This growth is being driven by the increasing prevalence of diabetes and the demand for more convenient and accurate blood glucose monitoring methods.
As the market grows, it is likely that we will see more M&A activity as companies look to consolidate their positions and gain access to new technologies and markets.
Engage with the HealthTech Community
HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb
HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk
HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digitall
The big question: will Apple enter the non-invasive continuous blood glucose monitoring market in 2024?
It is possible that Apple will enter the non-invasive continuous blood glucose monitoring (NGBGM) market in 2024. Apple has been working on healthcare initiatives for several years, and the company has a strong track record of innovation. Additionally, the Argonaut Project is a major step towards improving interoperability in healthcare, which would make it easier for Apple to develop an NGBGM product.
However, there are also some challenges that Apple would need to overcome in order to enter the NGBGM market. One challenge is the regulatory environment. The healthcare industry is heavily regulated, and Apple would need to comply with all applicable regulations in order to develop and sell an NGBGM product.
Another challenge is the cost. Developing an NGBGM product is a complex and expensive undertaking. Apple would need to invest significant resources in order to develop a product that meets the needs of patients, doctors, and healthcare providers.
Despite these challenges, I believe that it is possible that Apple will enter the NGBGM market in 2024. Apple has the resources and expertise to develop a successful product, and the healthcare industry is ripe for innovation.
Here are some of the factors that could influence whether or not Apple enters the NGBM market in 2024:
The progress of the Argonaut Project: The Argonaut Project is a major step towards improving interoperability in healthcare. If the project is successful, it would make it easier for Apple to develop an NGBM product that can communicate with other healthcare systems.
The regulatory environment: The healthcare industry is heavily regulated. Apple would need to comply with all applicable regulations in order to develop and sell an NGBM product.
The cost of development: Developing an NGBM product is a complex and expensive undertaking. Apple would need to invest significant resources in order to develop a product that meets the needs of patients, doctors, and healthcare providers.
The demand from patients and healthcare providers: There is a growing demand for NGBM products from patients and healthcare providers. If there is a strong demand for these products, Apple may be more likely to enter the market.
Overall, I believe that it is possible that Apple will enter the NGBM market in 2024. However, there are a number of factors that could influence whether or not Apple enters the market.
In recent news, Apple has been granted a patent for a non-invasive blood sugar monitoring system. This patent could be a sign that Apple is serious about entering the NGBM market.
However, it is still too early to say for sure when or if Apple will release such a product.
Potential acquirers in 2024
Some of the companies that are likely to be involved in M&A activity in the blood glucose monitoring market in 2024 include:
Dexcom: Dexcom is a leading provider of continuous glucose monitoring (CGM) systems. The company is likely to be a target for acquisition by a larger company.
Abbott Laboratories: Abbott Laboratories is a global healthcare company that is active in the blood glucose monitoring market. The company is likely to be involved in M&A activity in order to expand its presence in this market.
LifeScan: LifeScan is a subsidiary of Johnson & Johnson that is a leading provider of blood glucose monitoring systems. The company is likely to be a target for acquisition by a larger company.
Medtronic: Medtronic is a global healthcare company that is active in the blood glucose monitoring market. The company is likely to be involved in M&A activity in order to expand its presence in this market.
Senseonics: Senseonics is a developer of implantable continuous glucose monitoring (iCGM) systems. The company is likely to be a target for acquisition by a larger company.
These are just a few of the companies that are likely to be involved in M&A activity in the blood glucose monitoring market in 2024. The market is expected to grow significantly in the coming years, and this is likely to lead to increased M&A activity.
Key M&A trends predicted in the blood glucose monitoring market in 2024
Here are some of the key M&A trends that are expected to take place in the blood glucose monitoring market in 2024:
Partnerships between device manufacturers and healthcare providers: Device manufacturers and healthcare providers could partner to develop and market blood glucose monitoring solutions.
Joint ventures between companies in different parts of the value chain: Companies in different parts of the blood glucose monitoring value chain, such as device manufacturers, software developers, and healthcare providers, could form joint ventures to develop and market new solutions.
Larger companies will acquire smaller, more innovative companies: Larger companies are looking to acquire smaller, more innovative companies in order to gain access to new technologies and markets. This is especially true in the blood glucose monitoring market, where there are a number of small, but promising companies developing new technologies.
Companies will partner with pharmaceutical companies: Companies in the blood glucose monitoring market will partner with pharmaceutical companies in order to develop new products and services. This is because pharmaceutical companies have the expertise and resources to bring new products to market.
Companies will invest in research and development: Companies in the blood glucose monitoring market will invest in research and development in order to develop new technologies and products. This is because the blood glucose monitoring market is constantly evolving, and companies need to stay ahead of the curve.
Acquisitions of startups: Startups are developing innovative blood glucose monitoring technologies that could be acquired by larger companies.
Overall, the M&A trend in the blood glucose monitoring market is expected to continue in 2024. This is because the market is growing rapidly and there are a number of opportunities for consolidation.
Final Thoughts:
Apple's moonshot blood glucose monitoring project, codenamed E5, is a long-term research and development effort to develop a non-invasive way to measure blood glucose levels. The project is reportedly still in its early stages, but Apple has reportedly made significant progress in recent years.
The goal of the E5 project is to develop a device that can measure blood glucose levels without the need for needles or other invasive procedures. This would be a major breakthrough for people with diabetes, as it would make blood glucose monitoring more convenient and comfortable.
Apple is reportedly using a variety of technologies in the E5 project, including near-infrared spectroscopy, Raman spectroscopy, and ultrasound. These technologies are all capable of measuring glucose levels in the interstitial fluid, which is the fluid that surrounds cells.
The E5 project is a major undertaking, and it is not clear when Apple will be able to release a commercial product. However, the project is a sign of Apple's commitment to developing innovative health technologies.
Here are some of the challenges that Apple is facing in the E5 project:
Accuracy: The E5 project needs to develop a device that can measure blood glucose levels with the same accuracy as traditional methods.
Cost: The E5 project needs to develop a device that is affordable for people with diabetes.
Regulatory approval: The E5 project needs to obtain regulatory approval from the FDA and other regulatory agencies before it can be released to the public.
Despite these challenges, Apple is reportedly making good progress in the E5 project. The company has reportedly filed several patents related to the project, and it has hired a number of experts in the field of non-invasive blood glucose monitoring.
If Apple is successful in the E5 project, it could revolutionize blood glucose monitoring and make it easier for people with diabetes to manage their condition.
Engage with the HealthTech Community
HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb
HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk
HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital
